Bullous Pemphigoid disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: BLL006 MIFTS: 61	Bullous Pemphigoid Categories: Immune diseases, Rare diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Bullous Pemphigoid

MalaCards integrated aliases for Bullous Pemphigoid:

Name: Bullous Pemphigoid ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ¹⁴ ¹⁶ ⁷¹ ³¹ ³³

Senile Dermatitis Herpetiformis ¹⁹ ⁷¹

Benign Pemphigus ¹⁹ ⁷¹

Pemphigoid, Bullous ⁴³

Pemphigoid Bullous ⁵³

Old Age Pemphigus ¹⁹

Parapemphigus ¹⁹

Pemphigoid ¹⁹

Characteristics:

Prevelance:

1-9/100000 (France, Germany, United Kingdom, Switzerland) 1-5/10000 (Europe, Germany) ⁵⁸

Age Of Onset:

All ages ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Diseases of the skin and subcutaneous tissue

ICD11: ³³

Inflammatory dermatoses

Immunobullous diseases of the skin

Pemphigoid

Bullous pemphigoid

Orphanet: ⁵⁸

Rare skin diseases

External Ids:

Disease Ontology ¹¹ DOID:8506

ICD9CM ³⁴ 694.5

MeSH ⁴³ D010391

NCIt ⁴⁹ C84389

SNOMED-CT ⁶⁸ 77090002

ICD10 ³¹ L12.0

MESH via Orphanet ⁴⁴ D010391

ICD10 via Orphanet ³² L12.0

UMLS via Orphanet ⁷² C0030805

Orphanet ⁵⁸ ORPHA703

EFO ¹⁶ EFO_0007187

ICD11 ³³ 233308710

UMLS ⁷¹ C0030805 C0263311 C0392436

Sources

Summaries for Bullous Pemphigoid

GARD: ¹⁹ Bullous pemphigoid is a skin disorder characterized by large blisters. The blisters are usually located on the arms, legs, or middle of the body. In some people, the mouth or genitals are also affected. The blisters may break open and form ulcers or open sores. Bullous pemphigoid usually occurs in older persons and is rare in young people. Symptoms may come and go. Bullous pemphigoid is an autoimmune disorder which occurs when the body's immune system attacks and destroys healthy body tissue by mistake.

MalaCards based summary: Bullous Pemphigoid, also known as senile dermatitis herpetiformis, is related to epidermolysis bullosa acquisita and dermatitis herpetiformis. An important gene associated with Bullous Pemphigoid is HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1), and among its related pathways/superpathways are Signal Transduction and ERK Signaling. The drugs Hydrocortisone succinate and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include skin, salivary gland and bone, and related phenotypes are diabetes mellitus and autoimmunity

Orphanet: ⁵⁸ A rare autoimmune bullous skin disease characterized by acquired, subepidermal tense bullae occurring on normal of inflamed skin and that is typically widespread (occurring in the flexor regions of the proximal arms and legs, in the armpits, groin and the abdomen) and often associated with pruritus. The evolution is typically chronic with spontaneous exacerbations and remission.

Disease Ontology: ¹¹ A pemphigoid that is characterized by large blisters.

Wikipedia: ⁷⁵ Bullous pemphigoid (type of pemphigoid) is an autoimmune pruritic skin disease which typically occurs in... more...

Sources

Related Diseases for Bullous Pemphigoid

Diseases related to Bullous Pemphigoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 803)

#	Related Disease	Score	Top Affiliating Genes
1	epidermolysis bullosa acquisita	31.9	LAMC2 LAMA3 LAD1 ITGB4 HLA-DRB1 DST
2	dermatitis herpetiformis	31.6	IL5 HLA-DRB1 HLA-DQB1 CCL11
3	hypereosinophilic syndrome	31.6	RNASE3 IL5 CCL17 CCL11
4	pemphigoid gestationis	31.5	RNASE3 PPL HLA-DRB1 EVPL DST DSG3
5	dermatitis	31.5	RNASE3 IL5 DSG1 CCL17 CCL11
6	scabies	31.4	IL5 DST COL17A1
7	autoimmune disease	31.4	IL5 HLA-DRB1 HLA-DQB1 DSG3 DSG1 COL17A1
8	erythema multiforme	31.2	IL5 DSP CCL17
9	pseudomembranous conjunctivitis	31.2	PPL EVPL DST DSG3 DSG1 COL17A1
10	epidermolysis bullosa, junctional 4, intermediate	31.1	LAMB3 LAD1 DST COL17A1
11	dermatitis, atopic	31.1	RNASE3 IL5 CCL17 CCL11
12	contact dermatitis	31.1	RNASE3 IL5 CCL17 CCL11
13	pemphigus	31.1	PPL HLA-DRB1 HLA-DQB1 EVPL DST DSP
14	lichen planus	31.0	LAMC2 DST DSG3 DSG1 COL17A1
15	pompholyx	31.0	DST COL17A1
16	epidermolysis bullosa, junctional 1a, intermediate	30.9	LAMC2 LAMB3 LAMA3 ITGB4 COL17A1
17	alopecia	30.9	HLA-DRB1 DSP COL17A1
18	intermediate generalized junctional epidermolysis bullosa	30.8	LAMC2 LAMB3 LAMA3 ITGB4 COL17A1
19	basal cell carcinoma	30.8	LAMC2 ITGB4 ITGA6 DST COL17A1
20	pemphigus vulgaris, familial	30.8	PPL HLA-DRB1 EVPL DST DSP DSG3
21	benign chronic pemphigus	30.8	DSP DSG3 DSG1
22	allergic disease	30.8	RNASE3 IL5 CCL17 CCL11
23	pemphigoid	30.8	RNASE3 PPL PLEC LAMB3 LAMA3 ITGB4
24	epidermolysis bullosa	30.7	PLEC LAMC2 LAMB3 LAMA3 LAD1 ITGB4
25	ocular cicatricial pemphigoid	30.7	ITGB4 ITGA6
26	pemphigus foliaceus	30.7	PPL HLA-DRB1 EVPL DST DSP DSG3
27	chronic urticaria	30.7	RNASE3 IL5 HLA-DRB1 HLA-DQB1
28	chronic conjunctivitis	30.7	RNASE3 IL5 CCL11
29	esophagitis	30.7	RNASE3 IL5 DSG1 CCL11
30	conjunctival disease	30.7	RNASE3 IL5 CCL11
31	cicatricial pemphigoid	30.7	LAMC2 LAMA3 LAD1 ITGB4 ITGA6 HLA-DQB1
32	herpetiform pemphigus	30.6	DSG3 DSG1
33	keratoconjunctivitis	30.6	RNASE3 IL5 CCL11
34	allergic contact dermatitis	30.6	RNASE3 IL5 CCL17 CCL11
35	allergic asthma	30.6	RNASE3 IL5 CCL17 CCL11
36	common cold	30.6	RNASE3 IL5 CCL11
37	proteasome-associated autoinflammatory syndrome 1	30.5	RNASE3 IL5 CCL11
38	aspergillosis	30.5	IL5 HLA-DRB1 CCL17
39	junctional epidermolysis bullosa non-herlitz type	30.5	PLEC LAMC2 LAMB3 LAMA3 ITGB4 DST
40	mite infestation	30.5	IL5 DST COL17A1
41	silicosis	30.4	HLA-DRB1 HLA-DQB1 DSG1
42	conjunctivitis	30.4	RNASE3 IL5 CCL11
43	pemphigus erythematosus	30.4	DSP DSG3
44	chronic eosinophilic pneumonia	30.4	RNASE3 IL5 CCL11
45	respiratory failure	30.4	RNASE3 IL5 CCL17 CCL11
46	eosinophilic gastroenteritis	30.4	RNASE3 IL5 CCL11
47	gastroenteritis	30.4	RNASE3 IL5 CCL11
48	parasitic helminthiasis infectious disease	30.3	RNASE3 IL5 CCL11
49	rubella	30.3	IL5 HLA-DRB1 HLA-DQB1
50	bullous impetigo	30.3	DSG3 DSG1

Comorbidity relations with Bullous Pemphigoid via Phenotypic Disease Network (PDN):

Acute Cystitis	Decubitus Ulcer
Deficiency Anemia	Heart Disease
Pemphigus	Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Bullous Pemphigoid:

Sources

Symptoms & Phenotypes for Bullous Pemphigoid

Human phenotypes related to Bullous Pemphigoid:

⁵⁸ ³⁰ (show all 10)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	diabetes mellitus ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000819
2	autoimmunity ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002960
3	erythema ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0010783
4	macule ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0012733
5	weight loss ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001824
6	eczema ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000964
7	urticaria ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001025
8	abnormal blistering of the skin ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0008066
9	recurrent infections ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002719
10	psoriasiform dermatitis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003765

GenomeRNAi Phenotypes related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.14	CCL11 CCL17 COL17A1 DSG1 DSG3 DSP
2	no effect	GR00402-S-2	10.14	CCL11 COL17A1 DSG1 DSG3 DST HLA-DRB1

MGI Mouse Phenotypes related to Bullous Pemphigoid:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	10.21	CCL17 COL17A1 DSG3 DSP DST HLA-DQB1
2	digestive/alimentary	MP:0005381	10.02	DSG3 DSP DST HLA-DQB1 IL5 ITGA6
3	renal/urinary system	MP:0005367	10.01	COL17A1 DST HLA-DQB1 ITGA6 ITGB4 LAMB3
4	immune system	MP:0005387	10	CCL11 CCL17 COL17A1 DSG3 DSP DST
5	craniofacial	MP:0005382	9.86	DSG3 DSP DST ITGA6 ITGB4 LAMA3
6	respiratory system	MP:0005388	9.61	CCL11 DSG3 HLA-DQB1 IL5 ITGA6 ITGB4
7	integument	MP:0010771	9.44	COL17A1 DSG1 DSG3 DSP DST EVPL

Sources

Drugs & Therapeutics for Bullous Pemphigoid

Drugs for Bullous Pemphigoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Hydrocortisone succinate

Approved

Phase 4

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

3640 5754

Clobetasol

Approved, Experimental, Investigational

Phase 4

25122-46-7, 25122-41-2

2791 5311051 32798

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 4

67-97-0, 1406-16-2

5280795 10883523

Calciferol

Phase 4

Calcium, Dietary

Phase 4

Hydrocortisone 17-butyrate 21-propionate

Phase 4

Immunoglobulins, Intravenous

Phase 4

Immunoglobulin E

Phase 4

Calcium

Nutraceutical

Phase 4

7440-70-2

271

Benralizumab

Approved, Investigational

Phase 3

1044511-01-4

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Prednisone

Approved, Vet_approved

Phase 2, Phase 3

53-03-2

5865

Prednisolone phosphate

Approved, Vet_approved

Phase 2, Phase 3

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 2, Phase 3

52-21-1

Prednisolone

Approved, Vet_approved

Phase 2, Phase 3

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 2, Phase 3

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 2, Phase 3

83-43-2

4159 6741

Mycophenolic acid

Approved, Investigational

Phase 2, Phase 3

24280-93-1

446541

Levoleucovorin

Approved, Experimental, Investigational

Phase 2, Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Triamcinolone

Approved, Vet_approved

Phase 2, Phase 3

124-94-7

31307

Dapsone

Approved, Investigational

Phase 2, Phase 3

80-08-0

2955

Omalizumab

Approved, Investigational

Phase 3

242138-07-4

Rituximab

Approved

Phase 3

174722-31-7

Nicotinamide

Approved, Investigational

Phase 3

98-92-0

936

Doxycycline

Approved, Investigational, Vet_approved

Phase 3

564-25-0

54671203

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2, Phase 3

59-30-3

6037

Niacin

Approved, Investigational, Nutraceutical

Phase 3

59-67-6

938

Prednisolone hemisuccinate

Experimental

Phase 2, Phase 3

2920-86-7

4897

Cortisone

Experimental

Phase 2, Phase 3

53-06-5

222786

Immunoglobulins

Phase 3

Antibodies

Phase 3

gamma-Globulins

Phase 3

Rho(D) Immune Globulin

Phase 3

Gentamicins

Phase 3

Olive

Phase 3

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Antineoplastic Agents, Hormonal

Phase 2, Phase 3

Hormones

Phase 2, Phase 3

Hormone Antagonists

Phase 2, Phase 3

glucocorticoids

Phase 2, Phase 3

Anti-Inflammatory Agents

Phase 2, Phase 3

Immunosuppressive Agents

Phase 2, Phase 3

Anti-Bacterial Agents

Phase 2, Phase 3

Anti-Infective Agents

Phase 2, Phase 3

Antitubercular Agents

Phase 2, Phase 3

Methylprednisolone Acetate

Phase 2, Phase 3

584547

Antibiotics, Antitubercular

Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 62)

#	Name	Status	NCT ID	Phase	Drugs
1	Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid	Unknown status	NCT03926377	Phase 4
2	Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid	Unknown status	NCT02360202	Phase 4	Clobetasol Propionate cream treatment
3	An Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous Pemphigoid	Completed	NCT00472030	Phase 4	Omalizumab;prednisone
4	Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid.	Completed	NCT00525616	Phase 3	Mabthera
5	Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid	Completed	NCT02313870	Phase 3	clobetasol propionate + Methotrexate;clobetasol propionate alone
6	NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase III)	Completed	NCT01408550	Phase 3	NPB-01;Placebo
7	Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid.	Completed	NCT02993133	Phase 3	Cellcept® in autoimmune bullous dermatoses
8	Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid Compared to Conventional Topical Treatment	Recruiting	NCT05594472	Phase 3	Ozonated olive oil;Topical garamycin cream
9	A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)	Recruiting	NCT04612790	Phase 3
10	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid	Recruiting	NCT04206553	Phase 2, Phase 3	dupilumab;Matching Placebo;Oral corticosteroids (OCS)
11	A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid	Recruiting	NCT05267600	Phase 2, Phase 3	Prednisone
12	Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid	Recruiting	NCT03295383	Phase 3	Rituximab 1g IV;Cyclophosphamide 50Mg Oral Tablet;Placebo of Rituximab;Placebo Oral Tablet
13	Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone	Active, not recruiting	NCT04744623	Phase 2, Phase 3	large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP
14	An Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid	Not yet recruiting	NCT04128176	Phase 3	Rituximab combined with Omalizumab
15	A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)	Withdrawn	NCT05061771	Phase 3	nomacopan (rVA576)
16	Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid. An Open Prospective Study	Unknown status	NCT00802243	Phase 2	leflunomide
17	Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid.	Completed	NCT01705795	Phase 2	Mepolizumab (a-IL-5 antibody);Placebo
18	NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(PhaseⅡ).	Completed	NCT00809822	Phase 2	NPB-01;Placebo
19	Ixekizumab in the Treatment of Bullous Pemphigoid	Completed	NCT03099538	Phase 2	Ixekizumab
20	A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid	Completed	NCT00431119	Phase 2	Azathioprine or Mycophenolate mofetil
21	Rituximab in the Treatment of Patients With Bullous Pemphigoid	Completed	NCT00286325	Phase 1, Phase 2	Rituximab
22	A Phase IIa Open-label Single Arm Study of Safety and Efficacy of rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects	Completed	NCT04035733	Phase 2	rVA576
23	Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid	Completed	NCT04499235	Phase 2	Mometasone furoate;AKST4290;Placebo
24	An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid	Completed	NCT02226146	Phase 2
25	Phase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid	Completed	NCT00584935	Phase 1, Phase 2	Rituximab
26	The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis	Completed	NCT01582880	Phase 1, Phase 2	Riboflavin
27	Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody	Recruiting	NCT04563923	Phase 2	Avdoralimab (IPH5401)
28	Efficacy and Safety of Ustekinumab in Bullous Pemphigoid	Recruiting	NCT04117932	Phase 2	Ustekinumab
29	Phase IIa Multicenter Clinical Trial to Determine the Feasibility and Safety of the Use of Adipose-derived Mesenchymal Stem Cells (ASC) in the Treatment of Patients With Cicatricial Conjunctivitis Associated With Lyell's Syndrome, Stevens-Johnson Syndrome and Pemphigoid of the Mucous Membranes With Ocular Involvement.	Recruiting	NCT05520086	Phase 1, Phase 2	Single Dose;Double Dose
30	Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid	Recruiting	NCT05263505	Phase 2	Baricitinib 2 MG [Olumiant];Methotrexate;Azathioprine;Mycophenolate
31	Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Inflammatory Ulcerative Diseases	Recruiting	NCT04540133	Phase 2	dexamethasone 0.5mg/5ml solution;dexamethasone 0.5mg/5ml solution in Mucolox™
32	A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment	Terminated	NCT01688882	Phase 2	QGE031;Placebo
33	A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid	Terminated	NCT03286582	Phase 2	AC-203 1% Topical Ointment;Clobetasol 0.05% Topical Ointment
34	A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid.	Terminated	NCT01571895	Phase 2	DF2156A
35	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Withdrawn	NCT02126020	Phase 1, Phase 2	topical infliximab
36	The Improvement of Limbal Epithelial Culture Technique for the Treatment of Unilateral Limbal Insufficiency by Using Collagenase to Isolate Limbal Stem Cells	Unknown status	NCT02202642	Phase 1
37	Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study.	Completed	NCT02502903	Phase 1	BIV009
38	Clinical, Biological and Histological Characteristics of Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy: A National Retrospective Cohort Study	Unknown status	NCT04641884
39	Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? : Multicenter Retrospective Study in France and Switzerland	Unknown status	NCT03636763		data report
40	The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors: Α Ten-year Prospective Observational Study.	Unknown status	NCT04469582
41	Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission	Unknown status	NCT01265082
42	Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid	Unknown status	NCT02874079
43	Multicenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous Pemphigoid	Unknown status	NCT02837965		treatment with topical superpotent corticosteroid therapy;treatment with systemic therapy (methotrexate);treatment systemic therapy (prednisone);treatment with systemic therapy (prednisone);treatment with systemic therapy (doxycycline)
44	The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis	Unknown status	NCT03839069
45	Study of the Periodontal Microbiota in Gingival Cicatricial Pemphigoid Patients. Bicentric Pilot Study on 30 Patients.	Unknown status	NCT04555681
46	An Open Randomized Comparative Trial of Four Different Dressings for Cutaneous Coverage in Pemphigus and Pemphigoid	Unknown status	NCT02365675
47	Evaluation of Cytokines and Immunoglobulins in Serum and Blister Fluids Appeared Before Treatment and Subsequently Under Treatment in Bullous Pemphigoid	Completed	NCT03856840
48	Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid	Completed	NCT03272958
49	Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients	Completed	NCT03320798
50	Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid	Completed	NCT02883894

Search NIH Clinical Center for Bullous Pemphigoid

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

SULFAPYRIDINE PWDR

Cochrane evidence based reviews: pemphigoid, bullous

Sources

Genetic Tests for Bullous Pemphigoid

Sources

Anatomical Context for Bullous Pemphigoid

Organs/tissues related to Bullous Pemphigoid:

MalaCards : Skin, Salivary Gland, Bone, T Cells, Eye, Neutrophil, B Cells

Sources

Publications for Bullous Pemphigoid

Articles related to Bullous Pemphigoid:

(show top 50) (show all 7592)

#	Title	Authors	PMID	Year
1	C3d immunohistochemistry on formalin-fixed tissue is a valuable tool in the diagnosis of bullous pemphigoid of the skin. ⁵³ ⁶²	Pfaltz K...Kempf W	19863700	2010
2	Serum anti-BPAG1 auto-antibody is a novel marker for human melanoma. ⁵³ ⁶²	Shimbo T...Kaneda Y	20479946	2010
3	Sequential intramolecular epitope spreading of humoral responses to human BPAG2 in a transgenic model. ⁵³ ⁶²	Di Zenzo G...Yancey KB	19812601	2010
4	Circulating IgA and IgE autoantibodies in antilaminin-332 mucous membrane pemphigoid. ⁵³ ⁶²	Natsuga K...Shimizu H	19751242	2010
5	Immunoglobulin A antibodies against desmoglein 1, envoplakin, periplakin and BP230 in a patient with atypical bullous pemphigoid. ⁵³ ⁶²	Yamaki F...Hashimoto T	20507390	2010
6	Plakins in striated muscle. ⁵³ ⁶²	Boyer JG...Boudreau-Lariviere C	19768769	2010
7	Prevalence of autoantibodies to bullous pemphigoid antigens within the normal population. ⁵³ ⁶²	Fine JD	20083697	2010
8	Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. ⁵³ ⁶²	Wieland CN...Murray JA	20083688	2010
9	Conjunctival interleukin-13 expression in mucous membrane pemphigoid and functional effects of interleukin-13 on conjunctival fibroblasts in vitro. ⁵³ ⁶²	Saw VP...Calder VL	19910508	2009
10	Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. ⁵³ ⁶²	Probst C...Komorowski L	19737550	2009
11	Basement membrane changes in lichen planopilaris. ⁵³ ⁶²	Al-Refu K...Goodfield M	19522713	2009
12	Experimental animal models of bullous pemphigoid. ⁵³ ⁶²	Heimbach L...Liu Z	19755945	2009
13	Plasmin plays a role in the in vitro generation of the linear IgA dermatosis antigen LADB97. ⁵³ ⁶²	Hofmann SC...Franzke CW	19158842	2009
14	Pemphigoid gestationis: clinical and laboratory evaluation. ⁵³ ⁶²	Cobo MF...Aoki V	19936176	2009
15	Cicatrising conjunctivitis with anti-basement membrane autoantibodies in ectodermal dysplasia. ⁵³ ⁶²	Saw VP...Zillikens D	18815422	2008
16	Calcineurin/NFAT-dependent regulation of 230-kDa bullous pemphigoid antigen (BPAG1) gene expression in normal human epidermal keratinocytes. ⁵³ ⁶²	Aizu T...Sawamura D	18353617	2008
17	Expression of vinculin in autoimmune cutaneous diseases. ⁵³ ⁶²	Wohl Y...Brenner S	18327013	2008
18	Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. ⁵³ ⁶²	Feng S...Shao C	18289320	2008
19	Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. ⁵³ ⁶²	Ishiura N...Tamaki K	17920818	2008
20	Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari. ⁵³ ⁶²	Atzori L...Aste N	18833046	2008
21	Role of BP180NC16a-enzyme-linked immunosorbent assay (ELISA) in the diagnosis of bullous pemphigoid in China. ⁵³ ⁶²	Feng S...Shao C	18173596	2008
22	Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid. ⁵³ ⁶²	Leighty L...Liu Z	17879094	2007
23	Relative risk for cancer in mucous membrane pemphigoid associated with antibodies to the beta4 integrin subunit. ⁵³ ⁶²	Letko E...Ahmed AR	17524068	2007
24	A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. ⁵³ ⁶²	Fairley JA...Giudice GJ	17611576	2007
25	[Comparison of urinary proteomics between steroid-sensitive and steroid-resistant minimal change nephrotic syndrome in children]. ⁵³ ⁶²	Huang YJ...Chen RH	17959526	2007
26	14-3-3 sigma isoform interacts with the cytoplasmic domain of the transmembrane BP180 in keratinocytes. ⁵³ ⁶²	Li Y...Ghahary A	17443672	2007
27	Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. ⁵³ ⁶²	Sitaru C...Zillikens D	17697150	2007
28	Significance of IgG4 in the diagnosis of mucous membrane pemphigoid. ⁵³ ⁶²	Suresh L...Kumar V	17344074	2007
29	Paraneoplastic pemphigus. ⁵³ ⁶²	Zhu X...Zhang B	17683379	2007
30	Clinical and immunopathologic findings in oral lichen planus pemphigoides. ⁵³ ⁶²	Solomon LW...Kumar V	17531940	2007
31	[Paraneoplastic pemphigus]. ⁵³ ⁶²	Preisz K...Karpati S	17513251	2007
32	Coexistence of IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus. ⁵³ ⁶²	Mentink LF...Pas HH	17263817	2007
33	Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. ⁵³ ⁶²	Matsushita T...Sato S	17222220	2007
34	Structural analysis of the plakin domain of bullous pemphigoid antigen1 (BPAG1) suggests that plakins are members of the spectrin superfamily. ⁵³ ⁶²	Jefferson JJ...Liem RK	17161423	2007
35	Oral pemphigoid autoantibodies preferentially target BP180 ectodomain. ⁵³ ⁶²	Calabresi V...Di Zenzo G	17141573	2007
36	Relationship between cancer and oral pemphigoid patients with antibodies to alpha6-integrin. ⁵³ ⁶²	Malik M...Ahmed AR	17181734	2007
37	Antigen specificity in subsets of mucous membrane pemphigoid. ⁵³ ⁶²	Rashid KA...Ahmed AR	16810295	2006
38	Localisation of bullous pemphigoid antigen 180 (BP180) in cultured human keratinocytes: functionally relevant modification by calcium. ⁵³ ⁶²	Schmidt E...Zillikens D	16906396	2006
39	Detection of pemphigus desmoglein 1 and desmoglein 3 autoantibodies and pemphigoid BP180 autoantibodies in saliva and comparison with serum values. ⁵³ ⁶²	Andreadis D...Antoniades D	17026501	2006
40	Autoimmune subepidermal blistering diseases in Uganda: correlation of autoantibody class with age of patients. ⁵³ ⁶²	Mulyowa GK...Schmidt E	16961507	2006
41	Clinical and diagnostic features of mucous membrane pemphigoid. ⁵³ ⁶²	Endo H...Yamamoto H	17052040	2006
42	Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. ⁵³ ⁶²	Saeki H...Tamaki K	16859899	2006
43	Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. ⁵³ ⁶²	Asashima N...Tamaki K	16882171	2006
44	Comparison of reactivity and epitope recognition between sera from American and Italian patients with oral pemphigoid. ⁵³ ⁶²	Mignogna M...Ahmed AR	16792670	2006
45	IgG4 as the predominant IgG subclass in pemphigoides gestationis. ⁵³ ⁶²	Patton T...Jukic DM	16630180	2006
46	Epitopes in the linker subdomain region of envoplakin recognized by autoantibodies in paraneoplastic pemphigus patients. ⁵³ ⁶²	Zhang B...Zhu X	16470171	2006
47	Interferon-gamma down-regulates expression of the 230-kDa bullous pemphigoid antigen gene (BPAG1) in epidermal keratinocytes via novel chimeric sequences of ISRE and GAS. ⁵³ ⁶²	Kaneko T...Uitto J	16512878	2006
48	Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. ⁵³ ⁶²	Thoma-Uszynski S...Hertl M	16424234	2006
49	Identification of an epitope within human integrin alpha 6 subunit for the binding of autoantibody and its role in basement membrane separation in oral pemphigoid. ⁵³ ⁶²	Rashid KA...Ahmed AR	16424229	2006
50	Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. ⁵³ ⁶²	Oyama N...Black MM	16403100	2006

Sources

Genes for Bullous Pemphigoid

Genes related to Bullous Pemphigoid (2 elite genes):

(show all 35)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	HLA-DQB1	Major Histocompatibility Complex, Class II, DQ Beta 1	Protein Coding	42.7	Susceptibility factor ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8710911 23806156 12139680 (more) 10774139
2	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	37.57	Candidate gene tested ⁵⁸ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	8710911 23806156
3	DST	Dystonin	Protein Coding	51.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name Functions (show sections)	2180994 11069628 7517983 (more) 1904470 15186228 7814399 8752852 1987302 8618019 1512460 2182719 2070826 7682575 18353617 17161423 9205513 1379792 8349819 7738277 7706309 20479946 9640376 8688920 8027584 1717441 7963650 8370962 8662839 7574105 8432531 1401998 1712022 2276744 16512878 9182810 9536225 1998370 9920986 9666835 8040461 1686013 1748679 2186774 1739295 9714981 8949441 11899154 10504454 10417446 9665393 8874743 7492135 7504025 1390446 1390136 1426040 7682049 1702546 8514739 8408833 8829509 8915153 9068736 14761129 11600933 11028862 11011162 9366826 9292089 9115928 9087173 9077469 17959526 14576348 12603849 10215780 9699735 9415239 9144634 9084138 9077475 10636730 9892916 9666836 9114616 9039292 8593111 2045679 1709102 2022886 1707254 2200830 20083697 15560761 12707470 11406649 8345227 8494757 8494756
4	COL17A1	Collagen Type XVII Alpha 1 Chain	Protein Coding	41.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name (show sections)	9326393 12788530 12445194 (more) 11710917 14962097 15186228 8752852 10417629 9506450 1748679 7682575 9077469 12399776 9087447 10592407 9521865 8618019 7550320 1401998 17141573 15029263 11069622 9767278 7790367 8228259 9989788 1512460 10025864 8592065 7883981 7693763 10564722 10426902 9347799 8662839 20083688 8874389 7594563 8473327 10594735 16045678 9854043 8884529 9205513 10417517 10771483 16197389 9174592 9077475 19158842 17879094 17920818 16424234 17052040 16403100 16466621 10220817 9640376 9292090 9220968 8629821 1324962 19812601 19755945 19522713 18815422 18173596 18289320 16285180 14987253 12761182 12244200 10896391 10354023 19936176 9232815 12932258 11606928 11570526 11323216 11244233 10951252 10809861 10233336 9424087 9182810 8535614 20507390 10022517 10636730 9602711 9536225 7516396 8113038 1512461 17697150 17513251 16906396 16630180
5	DSG3	Desmoglein 3	Protein Coding	25.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18833046 17263817 15242953 (more) 17026501 10083884 7560455
6	DSG1	Desmoglein 1	Protein Coding	25.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18833046 8829509 9174592 (more) 15242953 20507390 10651711 7543545 17683379 17513251 17263817
7	DSP	Desmoplakin	Protein Coding	24.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1390446 2247105 7999603 (more) 1497365 7843961 7769263 8938451 9699735 16120143 1401305 8570960 9412476 17513251 1443026 8593111 17683379 8250577 9284106 9989789 10597135 16470171 1712022 9229116 9784047 19768769 1538540 10083884 10212812
8	ITGB4	Integrin Subunit Beta 4	Protein Coding	24.43	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8408921 1401998 11899157 (more) 9087447 11375975 7577595 12648237 15482329 8791519 7608519 17524068 17443672 10928271 17531940 15308120 9660880 12925388 16792670 16810295 11570526
9	PPL	Periplakin	Protein Coding	24.43	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15243525 9699735 16120143 (more) 17513251 17683379 20507390 9989789 16470171 10083884 10597135 14705806 19737550
10	EVPL	Envoplakin	Protein Coding	24.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15243525 8938451 9699735 (more) 16120143 9412476 17513251 17683379 20507390 9284106 9989789 16470171 9229116 10083884 10597135 19737550
11	LAD1	Ladinin 1	Protein Coding	22.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9666845 9665393
12	ITGA6	Integrin Subunit Alpha 6	Protein Coding	22.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11669480 16126949 9205513 (more) 9389789 7790367 17181734 17443672 7551559 1474190 16424229 15482329 16810295 16792670 11600933
13	IL5	Interleukin 5	Protein Coding	21.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11028861 1444583 11145840 (more) 9522998 10400817 12558956 10886144 9459128
14	PLEC	Plectin	Protein Coding	20.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10809861 8983017
15	LAMC2	Laminin Subunit Gamma 2	Protein Coding	20.42	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7544906 8357788 8027584 (more) 8482332 7551559
16	LAMA3	Laminin Subunit Alpha 3	Protein Coding	19.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12746470
17	LAMB3	Laminin Subunit Beta 3	Protein Coding	19.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9487212
18	RNASE3	Ribonuclease A Family Member 3	Protein Coding	19.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8393016 7751092 9522998 (more) 9602632 8554381
19	CCL11	C-C Motif Chemokine Ligand 11	Protein Coding	19.04	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11028861 14725564 11809592 (more) 14561178 10886144
20	CCL17	C-C Motif Chemokine Ligand 17	Protein Coding	17.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16859899
21	IVL	Involucrin	Protein Coding	17.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1575982 7509722
22	TNFSF13B	TNF Superfamily Member 13b	Protein Coding	16.81	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16882171 17222220
23	KRT14	Keratin 14	Protein Coding	16.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19522713 8314871
24	FCER2	Fc Epsilon Receptor II	Protein Coding	15.39	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8060916 15194147
25	KRT5	Keratin 5	Protein Coding	15.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14576607 19522713
26	CCL5	C-C Motif Chemokine Ligand 5	Protein Coding	14.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10325455
27	PLAU	Plasminogen Activator, Urokinase	Protein Coding	14.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8879451 8481985
28	SERPINF2	Serpin Family F Member 2	Protein Coding	14.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7688770 7523283
29	IL4	Interleukin 4	Protein Coding	14.22	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	IGHE	Immunoglobulin Heavy Constant Epsilon	Protein Coding	13.95	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9624579 8393016 15194147 (more) 8494749 10727301 17611576 19751242 8871665 12713582 12588369 1534730 9522998
31	TNF	Tumor Necrosis Factor	Protein Coding	13.95	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
32	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	13.86	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
33	IL6	Interleukin 6	Protein Coding	13.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
34	CD79A	CD79a Molecule	Protein Coding	13.31	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15186228 8409534 17263817 (more) 16175044 9506436 19863700 16961507 19751242 17344074 11736901 9640363 8478493 7741544 15117364
35	ELANE	Elastase, Neutrophil Expressed	Protein Coding	13.02	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Bullous Pemphigoid

Sources

Expression for Bullous Pemphigoid

Search GEO for disease gene expression data for Bullous Pemphigoid.

Sources

Pathways for Bullous Pemphigoid

Pathways related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

(show all 27)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.67	LAMC2 LAMB3 LAMA3 IL5 DST DSP
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.63	LAMC2 LAMB3 LAMA3 ITGB4 ITGA6 IL5
3	Integrin Pathway ⁶⁴ Show member pathways FAK1 Signaling ⁶⁴ GnRH Signaling ⁶⁴ Inhibition of Angiogenesis by TSP1 ⁶⁴ Transendothelial Migration of Leukocytes ⁶⁴ UPA-UPAR Pathway ⁶⁴	13.27	LAMC2 LAMB3 LAMA3 ITGB4 ITGA6 COL17A1
4	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	12.96	COL17A1 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
5	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.83	LAMC2 LAMB3 LAMA3 ITGB4 ITGA6
6	Beta-Adrenergic Signaling ⁶⁴ Show member pathways CDK5 Pathway ⁶⁴ Erythropoietin Pathway ⁶⁴ Insulin Pathway ⁷⁰ Insulin Receptor Pathway ⁶⁴	12.78	LAMC2 LAMB3 LAMA3 ITGB4 ITGA6
7	Collagen chain trimerization ⁶⁶ Show member pathways Anchoring fibril formation ⁶⁶ Assembly of collagen fibrils and other multimeric structures ⁶⁶ Blood Coagulation Cascade ⁶⁴ Collagen biosynthesis and modifying enzymes ⁶⁶ Collagen degradation ⁶⁶ Collagen formation ⁶⁶ Crosslinking of collagen fibrils ⁶⁶ Intrinsic Prothrombin Activation Pathway ⁶⁴	12.63	COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
8	Malignant pleural mesothelioma ⁷⁴	12.57	LAMC2 LAMB3 LAMA3 ITGB4 ITGA6
9	Extracellular matrix organization ⁶⁶ Show member pathways Degradation of the extracellular matrix ⁶⁶	12.5	PLEC LAMC2 LAMB3 LAMA3 ITGB4 ITGA6
10	Keratinization ⁶⁶ Show member pathways Formation of the cornified envelope ⁶⁶	12.47	PPL EVPL DSP DSG3 DSG1
11	COPI-independent Golgi-to-ER retrograde traffic ⁶⁶ Show member pathways Cell cycle Spindle assembly and chromosome separation ²² Cytoskeleton remodeling Keratin filaments ²² Cytoskeleton remodeling Neurofilaments ²² HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand ⁶⁶	12.4	DSP DST EVPL PLEC PPL
12	Cell junction organization ⁶⁶ Show member pathways Adherens junctions interactions ⁶⁶ Cell-Cell communication ⁶⁶ Cell-cell junction organization ⁶⁶ Cell-extracellular matrix interactions ⁶⁶ Localization of the PINCH-ILK-PARVIN complex to focal adhesions ⁶⁶ Nectin/Necl trans heterodimerization ⁶⁶ Regulation of cytoskeletal remodeling and cell spreading by IPP complex components ⁶⁶ SDK interactions ⁶⁶ Signal regulatory protein family interactions ⁶⁶ Tight junction interactions ⁶⁶ Type I hemidesmosome assembly ⁶⁶	12.37	PLEC LAMC2 LAMB3 LAMA3 ITGB4 ITGA6
13	MET promotes cell motility ⁶⁶ Show member pathways Beta1 integrin cell surface interactions ⁶¹ MET activates PTK2 signaling ⁶⁶ MET activates RAP1 and RAC1 ⁶⁶ MET activates RAS signaling ⁶⁶ MET interacts with TNS proteins ⁶⁶ MET Receptor Activation ⁶⁶ MET receptor recycling ⁶⁶ Signaling by MET ⁶⁶	12.32	LAMC2 LAMB3 LAMA3 ITGA6
14	Focal adhesion ⁷⁴	12.1	LAMC2 LAMB3 LAMA3 ITGB4 ITGA6
15	Non-integrin membrane-ECM interactions ⁶⁶ Show member pathways Alpha6 beta4 integrin-ligand interactions ⁶¹ Cell adhesion Endothelial cell contacts by non-junctional mechanisms ²² Laminin interactions ⁶⁶ Syndecan interactions ⁶⁶	11.99	LAMC2 LAMB3 LAMA3 ITGB4 ITGA6
16	RND3 GTPase cycle ⁶⁶ Show member pathways RND1 GTPase cycle ⁶⁶ RND2 GTPase cycle ⁶⁶	11.91	DST DSP DSG1
17	Apoptotic cleavage of cellular proteins ⁶⁶ Show member pathways Apoptosis induced DNA fragmentation ⁶⁶ Apoptotic cleavage of cell adhesion proteins ⁶⁶ Apoptotic execution phase ⁶⁶ Caspase-mediated cleavage of cytoskeletal proteins ⁶⁶	11.9	PLEC DSP DSG3 DSG1
18	Adhesion ³	11.87	PLEC ITGB4 ITGA6 DSP
19	Allograft rejection ⁷⁴	11.76	IL5 HLA-DRB1 HLA-DQB1
20	Small cell lung cancer ⁷⁴	11.72	LAMC2 LAMB3 LAMA3 ITGA6
21	Lung fibrosis ⁷⁴	11.57	IL5 DSP CCL11
22	Cell adhesion_ECM remodeling ²²	11.55	LAMC2 LAMB3 LAMA3
23	IL4-mediated signaling events ⁶¹	11.53	IL5 CCL17 CCL11
24	Validated transcriptional targets of TAp63 isoforms ⁶¹	11.48	ITGB4 EVPL DST
25	Th2 Differentiation ⁶⁵	11.39	IL5 CCL17 CCL11
26	a6b1 and a6b4 Integrin signaling ⁶¹	10.67	LAMC2 LAMB3 LAMA3 ITGB4 ITGA6 COL17A1
27	G-protein signaling_Rap2B regulation pathway ²²	10.51	LAMC2 LAMB3 LAMA3 ITGB4 ITGA6 IL5

Sources

GO Terms for Bullous Pemphigoid

Cellular components related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	intermediate filament	GO:0005882	10.18	PPL PLEC HLA-DRB1 EVPL DST DSP
2	cornified envelope	GO:0001533	10.07	PPL EVPL DSP DSG3 DSG1
3	basement membrane	GO:0005604	9.97	LAMC2 LAMB3 LAMA3 LAD1 ITGB4 DST
4	desmosome	GO:0030057	9.96	DSG1 DSG3 DSP EVPL PPL
5	cellular anatomical entity	GO:0110165	9.87	PPL PLEC LAMB3 LAMA3 EVPL DST
6	laminin-5 complex	GO:0005610	9.73	LAMB3 LAMA3
7	anchoring junction	GO:0070161	9.61	PPL PLEC ITGB4 EVPL DST DSP
8	hemidesmosome	GO:0030056	9.32	PLEC LAMA3 ITGB4 DST COL17A1

Biological processes related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	cell-cell adhesion	GO:0098609	10.07	LAMA3 ITGA6 DSP DSG3 DSG1
2	cell adhesion	GO:0007155	10.07	LAMC2 LAMB3 LAMA3 ITGB4 ITGA6 DST
3	wound healing	GO:0042060	10.02	DSP DST EVPL PLEC PPL
4	integrin-mediated signaling pathway	GO:0007229	10.01	LAMA3 ITGB4 ITGA6 DST
5	tissue development	GO:0009888	9.93	LAMC2 LAMB3 LAMA3
6	keratinocyte differentiation	GO:0030216	9.92	PLEC EVPL DSP
7	intermediate filament cytoskeleton organization	GO:0045104	9.85	DSP DST EVPL PLEC PPL
8	cell motility	GO:0048870	9.83	DST ITGB4 PLEC
9	epidermis development	GO:0008544	9.8	LAMC2 LAMB3 LAMA3 HLA-DRB1 EVPL DSP
10	nail development	GO:0035878	9.78	ITGB4 ITGA6
11	immunoglobulin production involved in immunoglobulin-mediated immune response	GO:0002381	9.51	HLA-DRB1 HLA-DQB1
12	antigen processing and presentation of peptide or polysaccharide antigen via MHC class II	GO:0002504	9.49	HLA-DRB1 HLA-DQB1
13	hemidesmosome assembly	GO:0031581	9.32	PLEC LAMA3 ITGB4 DST COL17A1

Molecular functions related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cadherin binding	GO:0045296	10.07	PPL PLEC LAD1 ITGA6 EVPL
2	integrin binding	GO:0005178	9.92	LAMA3 ITGB4 ITGA6 DST
3	extracellular matrix structural constituent	GO:0005201	9.86	COL17A1 LAMA3 LAMB3 LAMC2
4	MHC class II receptor activity	GO:0032395	9.58	HLA-DRB1 HLA-DQB1
5	structural constituent of cytoskeleton	GO:0005200	9.56	PPL PLEC HLA-DRB1 DSP
6	structural molecule activity	GO:0005198	9.53	PPL PLEC LAMB3 LAMA3 LAD1 EVPL
7	neuregulin binding	GO:0038132	9.46	ITGB4 ITGA6